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Proteostasis refers to the regulation of the cellular concentration, folding, interactions and
localization of each of the proteins that comprise the proteome. One essential element of
proteostasis is the disposal of misfolded proteins by the cellular pathways of protein degra-
dation. Lysosomes are an important site for the degradation of misfolded proteins, which
are trafficked to this organelle by the pathways of macroautophagy, chaperone-mediated
autophagy and endocytosis. Conversely, amyloid diseases represent a failure in proteosta-
sis, in which proteins misfold, forming amyloid deposits that are not degraded effectively
by cells. Amyloid may then exacerbate this failure by disrupting autophagy and lysosomal
proteolysis. However, targeting the pathways that regulate autophagy and the biogenesis
of lysosomes may present approaches that can rescue cells from the deleterious effects of
amyloidogenic proteins.
Introduction
Proteostasis refers to the regulation of the cellular concentration, folding, interactions and localization of
each the thousands of different proteins that comprise the proteome of an organism [1]. This is achieved by
the close integration of cellular pathways responsible for the synthesis, folding, post-translational mod-
ification, trafficking and degradation of proteins. One vital function of this proteostatic network is the
removal of any proteins that misfold. Conversely, the failure to degrade misfolded proteins can result in
disease [2] (Figure 1).
Cellular pathways for protein
degradation
The principal sites for protein degradation in cells are lysosomes and proteasomes [3]. Both are involved
in the constitutive turnover of cellular proteins; typically, short-lived proteins are degraded by protea-
somes, whereas lysosomes are responsible for the degradation of long-lived proteins. Misfolded proteins
also represent an important class of substrate for lysosomes and proteasomes [1]. These may include pro-
teins that require degradation because they fail to fold after translation, such as those encoded bymutated
sequences. Proteins that initially fold into their native conformations may also misfold due to environ-
mental or stochastic factors and require degradation.
Proteasomes are multi-subunit protease complexes that are present in the cytoplasm of cells [3]. Most
proteins degraded by proteasomes are tagged by polyubiquitination. These proteins are then fed into
the core of the proteasome where they are cleaved by the internal protease activities into short pep-
tides. Proteasomes can degrade a broad array of proteins, but they cannot cleave every protein, for ex-
ample the extended polyglutamine tracts present in disease-associated mutant forms of huntingtin [4].
Moreover, proteins need to be unfolded before they can access the proteasome’s catalytic core. Proteins
and proteinaceous aggregates that resist unfolding by chaperone activities must be degraded elsewhere.
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
Licence 4.0 (CC BY).
173
Essays in Biochemistry (2016) 60 173–180
DOI: 10.1042/EBC20160005
Figure 1. Cellular pathways of protein degradation remove misfolded proteins
Proteins may either fail to fold after their synthesis or fold into their native structure and then subsequently misfold. Cells must
dispose of these misfolded proteins and their aggregates in order to maintain proteostasis. Lysosomes and proteasomes
represent the principal sites for the degradation of misfolded proteins and play complementary roles in proteostasis.
Lysosomes are membrane-bound cytoplasmic organelles that contain a plethora of different hydrolases, which
degrade macromolecules and organelles [3]. These organelles have the capacity to degrade many fully folded, as well
as misfolded and aggregated, proteins. Once within the lumen of the lysosome, proteins are hydrolysed by an array of
proteases, known as cathepsins [5]. This generates free amino acids that can be used in cellularmetabolism. Lysosomes
therefore perform a complementary function to proteasomes in proteostasis, as shown by the lysosomal degradation
of polyglutamine tracts [4].
Sorting of misfolded proteins to the lysosome
for degradation
The pivotal role of lysosomes in proteostasis is exemplified by themultiple pathways used by cells to traffic proteins to
this organelle for degradation (Figure 2). Misfolded plasma membrane proteins are identified by CHIP [C-terminus
of Hsc70 (heat-shock cognate 70)-interacting protein 70]. CHIP is responsible for recruitment of the E3 ubiquitin
ligase, which ubiquitinates the plasma membrane protein, causing it to be endocytosed and ultimately delivered to
the lysosome [6]. Cytoplasmic proteins are delivered to the lysosome by autophagy, of which there are three pathways:
CMA (chaperone-mediated autophagy),macroautophagy andmicroautophagy [7].However, whereas bothCMAand
macroautophagy play important roles in proteostasis, the role of microautophagy in the degradation of proteins is not
well understood [8] and is therefore not discussed in this article. The endocytic pathway delivers extracellular proteins
to lysosomes, as well as proteins that are resident at the plasma membrane and in endosomes [6].
Delivery of misfolded proteins to lysosomes via
macroautophagy
Macroautophagy encapsulates cytoplasmic material, including cytosolic macromolecules and even entire organelles,
into characteristic double-membraned vesicles known as autophagosomes [6,10] (Figure 2). This cellular degradation
pathway is constitutive, althoughmacroautophagy can be enhanced by stresses such as starvation. ThemTOR (mam-
malian target of rapamycin) complex regulates macroautophagy [10]. During the initial hours of nutrient-starved
conditions or upon the addition of rapamycin, macroautophagy is activated. Macroautophagy initiation is controlled
by ULK1 (Unc-51-like kinase 1), mTOR negatively regulates ULK1 by phosphorylation. ULK1 interacts with the class
III PI3K (phosphoinositide 3-kinase) complex, which comprises Vps34 (vacuolar protein sorting 34), the adapter pro-
tein p150 and Beclin-1. Initiation consists of formation of an omegasome which elongates to form a phagophore. This
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Figure 2. Multiple pathways deliver proteins to lysosomes for degradation
(i) Misfolded plasma membrane proteins can be tagged for degradation via the E3 ubiquitin ligase CHIP. The resultant ubiquitinated proteins
are endocytosed into early endosomes, which mature into late endosomes. The misfolded plasma membrane proteins are then delivered to
lysosomes via the fusion of late endosomes with this organelle. (ii) Macroautophagy encapsulates cytoplasmic material, including soluble
cytosolic proteins and protein aggregates, into double-membraned vesicles that then fuse with the lysosome. (iii) In CMA, the chaperone
Hsc70 recognizes misfolded proteins and these are translocated into the lysosome by LAMP-2a. (iv) Microautophagy is associated with
the formation of invaginations in the lysosomal membrane and could also contribute to the delivery of proteins into the lysosome. ER,
endoplasmic reticulum. Adapted from [6,9].
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Figure 3. Proteins are recognized for CMA by a CMA-targeting motif
(i) The CMA motif may contain up to two hydrophobic residues [isoleucine (I), phenylalanine (F), leucine (L) or valine (V)], up to two positive
residues [arginine (R) or lysine (K)] and a single negatively charged residue [glutamate (E) or aspartate (D)] flanked at either the N- or
C-terminus of the pentapeptide by a single glutamine (Q) residue. This is often referred to as a KFERQ or KFERQ-like motif [12]. (ii) Protein
sequence of α-synuclein highlighting the CMA motif (bold and underlined) and potential CMA-targeting motif residues.
phagophore elongates further, encapsulating its cargo, before sealing to produce an autophagosome. The autophago-
some then fuses with a lysosome, delivering its contents for degradation by lysosomal hydrolases [10].
Macroautophagy enables folded proteins, as well asmisfolded proteins and protein aggregates, to be delivered to the
lysosomewithout needing to first unfold these proteins with chaperones [10]. Thusmacroautophagy can complement
the proteasome and CMA by degrading proteins and proteinaceous aggregates that resist unfolding by chaperone ac-
tivities. Initially, macroautophagy was thought to be a non-selective mechanism for the turnover of proteins. Owing
to its ability to encapsulate large volumes of cytoplasmic material, macroautophagy would enable both soluble pro-
teins as well as proteinaceous aggregates to be delivered to the lysosome. However, more recent studies have shown
that protein aggregates formed as a consequence of the failure of proteasomes to degrade proteins can be targeted se-
lectively to the macroautophagy pathway. This involves recognition by specific adaptor proteins, such as p62, which
link the aggregates to the assembling autophagosome [11].
Delivery of misfolded proteins to lysosomes via CMA
CMA involves the identification of misfolded proteins by Hsc70, a cytosolic chaperone [12] (Figure 2). Proteins
degraded by CMA have a five-amino-acid motif with the consensus sequence KFERQ (Lys-Phe-Glu-Arg-Gln)
(Figure 3). KFERQ-likemotifs are present in approximately one-third of soluble cytosolic proteins. The KFERQmotif
is buried in natively folded proteins. Misfolding of proteins may expose KFERQ-like motifs enabling Hsc70 binding.
The substrate protein is then unfolded and translocated across the lysosome membrane. This process requires Hsc70
on both sides of the lysosomal membrane and the binding of the substrate protein to LAMP-2a (lysosome-associated
membrane protein 2a) [12]. Binding drives the multimerization of LAMP-2a facilitating the translocation of the pro-
tein substrate across the lysosomal membrane [12].
Delivery of misfolded proteins to lysosomes via the endocytic
pathway
The cytosol is not the only cellular location in which proteins can misfold, and lysosomes are also involved in
the degradation of misfolded plasma membrane proteins. Lysosomes are the terminus of the endocytic pathway,
hence enabling plasma membrane proteins to be trafficked for degradation by lysosomal hydrolases. This is well
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documented for receptor down-regulation in cell signalling pathways, in which ligand-bound plasma membrane
receptors are ubiquitinated by E3 ubiquitin ligases, with the ubiquitin tag acting as a signal for the endocytic
trafficking of the receptor to the lysosome [6,9]. A similar process can be used to remove misfolded proteins from the
plasmamembrane. The E3 ubiquitin ligase CHIP, which recognizes misfolded proteins that are bound to chaperones,
ubiquitinates the cytoplasmic domains of misfolded membrane proteins [6]. For example disease-associated muta-
tions in the hERG (human ether-a-go-go-related gene) K+ channel result in its CHIP-dependent ubiquitination
and trafficking via the endocytic pathway to lysosomes for degradation [13].
Amyloid diseases and their interrelationship
with protein degradation by lysosomes
Amyloid diseases, collectively known as the amyloidoses, represent a failure in proteostasis. This is because pro-
teins are able to misfold into aggregates that are not cleared effectively by the pathways of protein degradation [14].
Irrespective of the precursor protein’s sequence or structure, amyloid formation is associated with proteins aggregat-
ing into fibrils with a cross-β molecular architecture [15,16]. Deposits of amyloid can form within cells, such as in
Parkinson’s disease, although, in many diseases, amyloid forms extracellular deposits, e.g. DRA (dialysis-related amy-
loidosis) [15]. Amyloid fibrils, as well as oligomers formed during either the assembly or the disassembly of fibrils,
can be toxic to cells by damaging cellular membranes, disrupting cellular physiology and may ultimately cause cell
death [15,16]. Crucially, one important element of cellular physiology that can be disrupted by amyloid is protein
degradation by lysosomes. This may not only exacerbate amyloid formation by increasing the level of proteins that
can assemble into amyloid, but also have an impact on other cellular processes by reducing the degradation of other
proteins.
The pathological interplay between lysosomes and amyloid is exemplified in Parkinson’s disease [17]. In Parkin-
son’s disease, α-synuclein aggregates into amyloid that is a major component of Lewy bodies which are cytoplasmic
inclusions that are a primary histological hallmark of this neurodegenerative disorder [18]. α-synuclein amyloid can
also be transmitted between cells, seeding aggregation of the protein in previously healthy cells [19]. Lysosomes are an
important site for the degradation of α-synuclein [12], as such any reduction in either autophagy or in the capacity of
lysosomes to degrade α-synuclein will result in increased levels of this protein, a major risk factor in its aggregation.
Reduced proteolytic activity in lysosomes can also enhance the transmission of α-synuclein amyloid between cells
[20]. A reduced capacity of cells to degrade proteins is a feature of aging andmay explain, at least in part, the increased
incidence of sporadic Parkinson’s disease with age [1]. Moreover, cathepsin D, LAMP-2a and Hsc70 are reduced in
dopaminergic neurons of subjects with Parkinson’s disease, suggesting an impairment in the ability of neurons to
deliver α-synuclein to lysosomes and in the subsequent degradation of the protein [21].
CMA is thought to be amajormechanism for the degradation of α-synuclein in healthy cells [12], with α-synuclein
containing the KFERQ-like motif FVKKDQ (Phe-Val-Lys-Lys-Asp-Gln) (Figure 3). The A30P and A53T dominant-
negative mutants of α-synuclein, which are associated with early onset familial forms of Parkinson’s disease, inhibit
CMA [22]. These mutant proteins bind to LAMP-2a, but are not transported across the lysosome membrane, result-
ing in the inhibition of CMA [22]. Similarly, high levels of wild-type α-synuclein can disrupt CMA [23]. Crucially,
inhibition of CMA not only promotes the formation of α-synuclein amyloid, presumably due to increased levels of
the protein, but also affects the degradation of other cellular proteins. One such protein is the neuronal survival fac-
tor MEF2D (myocyte enhancer factor 2D), which, as a result of reduced CMA, accumulates in an inactive form in
the cytoplasm [23]. In addition, α-synuclein amyloid can disrupt macroautophagy, as Lewy body-like α-synuclein
amyloid formed in cultured cells, resist degradation and cause a reduction in the clearance of autophagosomes [24].
Although Parkinson’s disease is associated with formation of amyloid fibrils within the cytoplasm of cells, in many
other amyloid disorders fibrils form extracellular deposits [15]. Lysosomes, however, are also vulnerable to extracel-
lular amyloids, as material from outside of cells can access lysosomes via the endocytic pathway. We have shown,
using β2m (β2-microglobulin), the culprit protein of DRA, that, if the amyloid fibrils are small enough, ∼300 nm in
length, they can be readily endocytosed by cells and trafficked to lysosomes [25]. Once within lysosomes, β2m fibrils
resist degradation and inhibit the proteolysis of endocytosed proteins by lysosomes [25]. Whether this inhibition is
due to overwhelming lysosomal proteases with hard-to-digest protein or another mechanism is unclear, but the inhi-
bition of protein degradation in lysosomes could also have an impact on autophagy. A role for lysosome dysfunction
has also been reported in immunoglobulin light chain amyloidosis [26]. Exposure of cells to immunoglobulin light
chain amyloid results in lysosome dysfunction and the disruption of autophagy, specifically reducing the clearance of
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autophagosomes [26]. This has parallels with the effects of intracellular α-synuclein aggregates on macroautophagy
[24].
Enhancing protein degradation by lysosomes
to reduce amyloid toxicity
Since many studies suggest an interrelationship between amyloid diseases and dysfunction of protein degradation
in lysosomes, could enhancing autophagy and lysosome function provide a way to treat these devastating disorders?
mTOR is a negative regulator of macroautophagy and its inhibition with rapamycin stimulates macroautophagy [10].
Rapamycin can also restore the clearance of autophagosomes in cells exposed to light chain amyloid and reduce tox-
icity associated with this amyloid [26]. Overexpression of sirtuin-1 can also suppress the formation of α-synuclein
amyloid in cell and animal models and it is thought to act via the induction of autophagy [27]. An alternative target
is TFEB (transcription factor EB), which functions as a master regulator of lysosomal biogenesis and autophagy [28].
Overexpression of TFEB or its activation with HPβCD (2-hydroxypropyl-β-cyclodextrin) promotes the clearance
of α-synuclein amyloid via the enhancement of macroautophagy in cells overexpressing α-synuclein [28]. More-
over, TFEB overexpression in a mouse model of Parkinson’s disease enhances expression of proteins associated with
macroautophagy and lysosomes, and crucially protects neurons from α-synuclein toxicity [29].
Activating lysosomal biogenesis and autophagy may be one approach to enhance lysosome function in amyloid
diseases, but another is to target the fibrils themselves. Hsp70 (heat-shock protein 70) is a chaperonewhose expression
is induced by cellular stress, and, although predominantly cytosolic, the protein is also localized to the lysosome. We
have found that incubation of cells with Hsp70 can prevent the inhibition of lysosomal proteolysis by β2m fibrils
[30]. Hsp70 may act by binding to and stabilizing β2m fibrils preventing their disassembly into toxic oligomers at the
mildly acidic pH they would encounter in the endocytic pathway [30].
Conclusions
Lysosomes are a key component of the cellularmachinery thatmaintains proteostasis, and these organelles play a cen-
tral role in the degradation of misfolded proteins and their aggregates. The importance of lysosomes in proteostasis
is highlighted by the multiple cellular pathways used by cells to identify misfolded proteins for delivery to lysosomes.
CMA, macroautophagy and the endocytic pathway traffic misfolded proteins to lysosomes. The role of microau-
tophagy is less well understood, but, as a pathway for delivery of material to lysosomes, it could also contribute to
proteostasis. Amyloid diseases in effect correspond to a failure in proteostasis. In some instances, they may be associ-
ated with a reduced ability of cells to deliver proteins to lysosomes, thus resulting in the accumulation of proteins that
can assemble into amyloid. Aging is associated with a reduced cellular proteolytic capacity and may, at least in part,
explain why amyloid diseases are more common in older subjects. Amyloid precursors and amyloid can also disrupt
the delivery of proteins to the lysosome via autophagy and impair proteolysis in lysosomes. Are amyloid diseases
therefore a vicious cycle in which amyloid exacerbates the reduction in cellular proteolytic capacity, resulting in yet
further production of amyloid? Whereas amyloid can exhibit toxic properties, disruption of autophagy will also have
an impact on other cellular functions and may be a downstream pathological consequence of amyloid formation.
Disruption of lysosomal proteolysis could also have an impact on the degradation of plasma membrane proteins.
Despite the increasing evidence of impaired lysosome function in amyloid disease, lysosomes are an underutilized
drug target in the treatment of these disorders. Increasing autophagy and the biogenesis of lysosomes via targeting
TFEB-dependent transcription or mTOR signalling may provide new therapeutic routes to treat these devastating
disorders.
Summary
• The degradation of misfolded proteins is an essential element of proteostasis.
• Lysosomes are degradative organelles that are responsible for the breakdown of proteins and other cellular
components.
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• Misfolded proteins are sorted to lysosomes via chaperone-mediated autophagy, macroautophagy and en-
docytosis.
• Amyloid diseases, such as Parkinson’s disease, represent a failure in proteostasis in which proteins misfold
into amyloid aggregates.
• Amyloid disrupts autophagy and the degradation of proteins in lysosomes, thus exacerbating this failure in
proteostasis.
• Promoting autophagy and the formation of new lysosomes may protect against amyloid diseases.
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